Sign inJoin
Company / Finance

DANAHER CORP /DE/

DHR · NYSE

Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.

FollowAdd to WatchlistAsk Question
NYSEDHRStock ResearchProof GateDANAHER CORP /DE/Company Deep Dive
Latest ReportJun 5, 2026Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?View report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters2 company reports
Latest Thesis

Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?

Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.

Jun 5, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
DANAHER CORP /DE/Vs Agilent: Which Life Science Giant Wins The Recurring Revenue Jun 5, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 2 reports ->
ReportTypeUpdatedReadActions
Danaher Vs Agilent: Which Life Science Giant Wins The Recurring Revenue War?Danaher and Agilent both sell into durable lab workflows, but the winner depends on recurring mix, margin quality, and cash conversion.NYSEJun 5, 2026Research reportReadSlides
Danaher: life-science quality has to show up in bioprocess recovery and cash conversionDanaher reported 2025 revenue of $24.57 billion and Q1 2026 revenue of $5.95 billion. The thesis depends on bioprocess recovery, diagnostics demand, operating leverage, acquisitions and cash conversion.NYSEMay 20, 2026Research reportReadSlides